L 739943
Latest Information Update: 15 Aug 2002
Price :
$50 *
At a glance
- Originator Merck & Co
- Class Hormones
- Mechanism of Action Growth hormone releasing factor agonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- No development reported Somatotropin deficiency
Most Recent Events
- 23 Feb 1999 New profile
- 23 Jun 1998 Preclinical development for Somatotropin deficiency in USA (PO)